Stockreport

European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors

Pfizer, Inc.  (PFE) 
Last pfizer, inc. earnings: 4/28 06:45 am Check Earnings Report
PDF In the EU, HYMPAVZI is the first once-weekly subcutaneous treatment approved for eligible people living with severe hemophilia B and the first to be administered via a p [Read more]